Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

ALS and Alzheimer’s Treatment Shows Promise as Disease Path Regulator

By Genervon Biopharmaceuticals LLC | December 28, 2016

ALS and Alzheimer’s disease bioinformatics reports confirm GM6’s role as regulator of disease-relevant pathways.

Genervon Biopharmaceuticals LLC reported that in advance of the upcoming JP Morgan Healthcare Conference in San Francisco in January it is publishng the confidential list of genes associated with Amyotrophic Lateral Sclerosis (ALS) (89 genes) and Alzheimer’s disease (84 genes) that are modulated by GM6 to potentially bring homeostasis to these progressive, incurable and fatal neurodegenerative diseases.

GM6 is modeled upon an endogenous embryonic-stage motoneuronotrophic factor regulator that controls differentiation and development of the human nervous system while further potentially monitoring distress signals and coordinating responses to restore homeostasis. GM6 binds specifically to the beta sub-unit of the tyrosine kinase of the Insulin Receptors, IGF1 Receptors and IGF2 Receptors, to activate the monitoring and repair mechanism in the brain. GM6 has been demonstrated to be safe in phase 1 and three phase 2 trials (ALS, PD and Ischemic Stroke).

Most, if not all, ALS and Alzheimer’s disease clinical trials have failed because conventional drug design has narrowly focused only on single targets believed to be associated with ALS or AD pathogenesis. Genervon has now shown that GM6 modulates 89 ALS-associated genes by at least twofold along with 84 AD-associated genes. These genes were associated with a diverse set of pathways and disease-associated processes that are consistent with our unique multi-target drug design strategy based upon an endogenous regulator.

Genervon’s ALS poster is now available online showing the 89 ALS-associated genes that are modulated by GM6. Also now available online is Genervon’s 84 AD-associated genes that are modulated by GM6.

Genervon discovered and developed GM6 for a range of neurological disorders with a primary focus on neurodegenerative diseases including Amyotrophic Lateral Sclerosis, Parkinson’s disease, Muscular Dystrophy, Huntington Disease and Alzheimer’s disease. Genervon is planning a phase 3 clinical trial for ALS in 2017.

(Source: Business Wire)


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50